Study aims to pinpoint sweet spot for GIST drug dosing
NCT ID NCT07614841
First seen Jun 05, 2026 · Last updated Jun 16, 2026 · Updated 2 times
Summary
This study looked at 328 people with intermediate or high-risk gastrointestinal stromal tumors (GIST) who took imatinib after surgery. The goal was to find the best dose range that prevents the tumor from coming back while keeping side effects low. Researchers measured drug levels in the blood and tracked tumor recurrence or death over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.